Background
The association between gastroesophageal reflux (GERD) and chronic obstructive pulmonary disease (COPD) has been previously investigated [
1]. Cross-sectional studies with limited sample size have reported, with some exeptions, that esophageal disease-related symptoms are more common and more severe in COPD patients than in other general medicine patients [
2‐
4]. Excess reflux, as determined by pH-monitoring, has also been documented to be higher in COPD [
5]. GERD has also been associated with more frequent COPD exacerbations [
6,
7]. The cause of this important association is unknown, but these data suggest not only that is GERD more common in COPD, but also that by increasing exacerbations, GERD may alter COPD presentation and course.
We hypothesized that COPD patients with GERD would have poorer QOL and more frequent exacerbations, but that the use of GERD-controlling medications, proton-pump inhibitors (PPIs) in particular, could modify these associations. To test this hypothesis, in the current observational study, combining cross-sectional and longitudinal data, we comprehensively evaluated clinical, physiologic and imaging differences between COPD patients with versus without a physician-based diagnosis of GERD. We also present an examination of how comorbid GERD impacts different measures of COPD-related health status and exacerbations.
Discussion
The analysis of a large cross-sectional multicenter study of patients with a wide range of COPD severities provides evidence of a significant association between the presence of GERD and both more symptomatic disease and poorer health status. We found that GERD is frequently found among COPD patients, and that COPD patients with coexistent GERD experience worse QOL (SGRQ), greater dyspnea (MMRC), and more frequent exacerbations during follow-up. These associations were maintained in multivariate analysis, independent of the effect of age, gender, severity of airflow obstruction, current smoking history and BMI. Importantly, these associations persisted after adjusting both for therapeutic PPI use and for the imbalance of other covariates associated with GERD diagnosis. Based on additional analysis of the GERD-PPi use interaction (model 3), we also discovered that PPIs use itself could be associated with more frequent exacerbations, but also with improved health-related QOL, as measured by SGRQ.
The 29.1% prevalence of physician-diagnosed GERD in our population is higher than the 16.5% reported by Bor [
3], which used different disease-specific questionnaires; it is lower than reports based on continuous esophageal pH monitoring [
5], but within the same range of other reports based on frequency of symptoms [
4] and self-report data [
19] in different clinical settings and in different countries [
20]. Our finding of a similar degree of airflow obstruction, measured by FEV
1% predicted, among COPD patients regardless of GERD diagnosis agrees with and greatly extends data presented in smaller series [
2,
5]. Interestingly, even with similar spirometry values, our participants with GERD had more intense bronchodilator and anti-inflammatory treatment, most probably in response to more frequent symptoms and exacerbations. The slightly greater frequency of GERD in women with COPD agrees with general population-based studies [
21] and recent inquires of healthcare utilization in the US [
22]. Whether this greater frequency of GERD in women with COPD is casually responsible of the established finding from multiple studies that women with COPD also suffer more frequent exacerbations [
23,
24], is an important topic for future investigation in this and other large longitudinal studies.
Although anticipated, our finding that multiple comorbidities were significantly more frequent in COPD patients with GERD is significant given our standardized physiological and radiographic characterization of COPD phenotypes and the potential to look for genetic association between COPD and its comorbidities in future analysis of this cohort. Those GERD-associated comorbidities in COPD included cardiovascular diseases, both as manifestations of established disease (including myocardial infarction, coronary artery disease, stroke/TIA), as well as cardiovascular risk factors (including obesity, current tobacco use, hypertension, and hyperlipidemia). Clustering of these comorbidities could reflect shared risk factors (obesity and diet) or a common inflammatory process, ultimately affecting the progression of COPD [
25]. We also tested if differences in our findings are explained by other factors (e.g. sleep apnea), and found that the GERD-COPD outcomes relations are maintained in the presence or absence of sleep apnea (Additional file
1: Table S1). The higher frequency of poor outcomes among participants with GERD in our longitudinal study supports the clinical suspicion that GERD could be an indicator of more frequent comorbidities.
We attempted to overcome two major limitations of previous observational studies examining the association between GERD and COPD. The first is the already described finding of clustering of comorbidities and poorer baseline functional status of those with GERD, which complicates isolating the effect of GERD alone. Hence, we performed a propensity analysis to identify additional factors associated with a diagnosis of GERD, and showed that the association between GERD and worse COPD outcomes were maintained. A second novel feature of our study is that we adjusted for PPI use and GERD-PPI use interactions. The independent association of PPI use with exacerbations and QOL may be due to confounding-by-indication, such that such individuals were deemed “sicker” by their physicians and therefore more likely to receive PPI therapy for their GERD. Our results overall, however, support a relationship between GERD and poor COPD outcomes, even appropriately controlling for the effect of medications.
It is noteworthy that our COPD patients with GERD more frequently displayed clinical characteristics of the chronic bronchitis predominant COPD phenotype recently described using data from this same cohort [
26]. Sputum production is gaining more acceptance as a predictor of increased risk for frequent exacerbations and for response to specific therapies [
27]. It is possible that the presence of GERD increases bronchial inflammation in COPD patients; however, we did not find a difference in airway disease measures assessed via imaging between those with GERD versus without GERD. Others have reported an association between an inflammatory marker, exhaled breath condensate pH, and GERD symptoms in COPD patients [
4], but further studies are needed to understand fully this potential relationship and its potential treatment implications.
The finding that GERD in COPD patients was associated with poorer QOL and more severe dyspnea agrees and significantly extends previous descriptions. In a study of 86 patients with COPD who answered a questionnaire to identify GERD symptoms, Rascon-Aguilar et al. [
28] showed univariate differences in SF-36 QOL scores related to the presence GERD symptoms, of the same magnitude we detected. We extend those findings to show that the association between reflux and poorer health-related QOL (measured with the SGRQ questionnaire) persists in multivariate analyses controlled for the effects of age, gender, pulmonary function, current smoking, and BMI. Importantly, the statistically significant effect in our data persists after controlling for medication. Although GERD therapy has been reported to improve QOL among the general population [
29], whether the same occurs among COPD patients is unclear.
The current finding that GERD is significantly associated with an exacerbation history also agrees with Hurst et al. [
7], who found an association with similar strength, but who did not control for the effect of PPIs use. The consistent results from different research designs in different populations [
7,
30] point towards a significant relationship between GERD and COPD exacerbations, and provide a robust body of evidence to give strong consideration to this factor as a potential disease-modifying intervention. At least one small study has tested the concept of using PPIs in COPD patients with no reflux symptoms [
31], and found a lower number of exacerbations after treatment with lansoprazole. However, our data generate additional questions about the potential use of PPIs to modify some COPD outcomes, as the association differed in our study depending on whether the outcome is QOL or exacerbation frequency. We have highlighted to the possibility of confounding-by-indication in the use of PPIs, which needs to be addressed in future studies. An intriguing possibility, which will require additional investigation, is that control of acid aspiration improves QOL, but that the association of GERD with increased exacerbation frequency relates less closely to acid aspiration than to changes in the community structure of the lung microbiome [
32], as suggested by findings of higher frequency of pneumonia among PPIs users in the general population [
33,
34].
Our study has several limitations. GERD diagnosis was based on self-report of a physician diagnosis, not on pH probe measures or specific questionnaires, which is potentially subject to recall bias. Furthermore, even physician diagnosis of GERD may not correlate with pH probe testing. Additionally, the design of COPDGene is not population-based, although it is inclusive of all levels of COPD severity and includes subjects recruited across the country at a wide variety of clinical centers. Whether the associations between the outcomes of interest and GERD therapy are restricted to PPIs, and not to antihistamines or other anti-GERD medications, is difficult to answer; only 3.3% of our participants were exposed to antihistamines, limiting the power for specific analysis. The current study was not designed to ascertain compliance or persistence on medications, and inquired about PPIs at inclusion, not persistence on therapy, a factor potentially affecting results in longitudinal studies. The strengths of our study include the extensive clinical and epidemiological characterization of the participants; the number and heterogeneity of subjects with versus without GERD included in the analysis; and our efforts to control for confounders common in observational studies, such as clustering of comorbidities and ignoring the effect of concurrent treatments.
We conclude that presence of GERD in COPD is associated with increased symptoms, poorer health-related QOL and increased frequency of exacerbations, even after adjusting for a self-reported use of GERD-related medication. Because a history of GERD identifies COPD patients at risk for poorer clinical outcomes, our results imply that identification and management of GERD should be considered part of optimal clinical management of COPD. Further research in the area is neccesary. Clinical trials to identify and control GERD to improve COPD outcomes should be considered.
Competing interests
The authors have reported the following conflicts of interest: Dr. Crapo received travel accommodations from AstraZeneca. Dr. F.J. Martinez has been a member of advisory boards for Actellion, Ikaria, Merck, Pearl, Pfizer, Jannsen, GlaxoSmithKline plc, Schering Plough, Novartis AG, Nycomed, Genzyme, Forest/Almirall, MedImmune, AstraZeneca, Potomac, Bayer, Elan, Talecris, and Roche. He has been on the speaker’s bureau for Forest/Almirall, Nycomed, Bayer, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, France Foundation, MedEd, NACE, and AstraZeneca. He has also been a member of steering committees for studies supported by Altana/Nycomed, GlaxoSmithKline, Gilead, Actelion, Johnson/Johnson, Mpex, UCB, and the National Institutes of Health. He has been an investigator in trials supported by Boehringer Ingelheim and Actelion. Dr. Han participated in advisory boards for Boehringer Ingelheim GmbH, Pfizer, GlaxoSmithKline plc, Genentech, Novartis, Forest and Medimmune; participated on speaker’s bureaus for Boehringer Ingelheim GmbH, Pfizer, GlaxoSmithKline plc, Grifols Therapeutics, Forest and the National Association for Continuing Education, and WebMD; has consulted for Novartis and United Biosource Corporation; and has received royalties from UpToDate and ePocrates. Drs. C.H. Martinez, Okajima, Murray, Silverman, Lee, Regan, Curtis and Hatabu, have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Authors’ contributions
CHM, MKH, SH, FJM, JLC, GRW, EAR contributed to the design, data collection, data analysis and interpretation and drafted the manuscript. YO, EKS, JHL, JDC, HH contributed to the design, data analysis and interpretation and drafted the manuscript. All authors have given final approval of the version to be published.